Efficacy and safety of abemaciclib alone and with PI3K/mTOR inhibitor LY3023414 or galunisertib versus chemotherapy in previously treated metastatic pancreatic adenocarcinoma: A randomized controlled trial.

E Gabriela ChioreanVincent PicozziChung-Pin LiMarc PeetersJoan MaurelJaswinder SinghTalia GolanJean-Frédéric BlancSonya C ChapmanAnwar M HussainErica L JohnstonHoward S Hochster

Published in: Cancer medicine (2023)

In patients with pretreated metastatic PDAC, abemaciclib-based therapy did not improve DCRs or PFS compared with SOC chemotherapy. No treatment arms advanced to Stage 2. Abemaciclib remains investigational in patients with PDAC.

Keyphrases

squamous cell carcinoma
small cell lung cancer
locally advanced
cell proliferation
clinical trial
radiation therapy
mesenchymal stem cells
bone marrow
newly diagnosed
study protocol